Progress in mechanisms and immunological treatment of chronic mucocutaneous candidiasis associated with congenital IL-17 pathway deficiency
10.3760/cma.j.issn.0254-5101.2020.01.013
- VernacularTitle: IL-17相关信号通路分子先天免疫缺陷在慢性黏膜皮肤念珠菌病中的研究及免疫治疗进展
- Author:
Dongmei SHI
1
;
Weida LIU
2
Author Information
1. Department of Dermatology & Laboratory of Medical Mycology, Jining No. 1 People′s Hospital, Jining 272001, China
2. Department of Mycology, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
- Publication Type:Review
- Keywords:
Chronic mucocutaneous candidiasis;
Candidia albicans;
IL-17
- From:
Chinese Journal of Microbiology and Immunology
2020;40(1):74-82
- CountryChina
- Language:Chinese
-
Abstract:
Chronic mucocutaneous candidiasis (CMC) is a rare, persistent and recurrent infection affecting skin, nails, and oral and genital mucosae. It is mainly caused by Candida albicans and hard to be cured with routine antifungal therapy. Usually, CMC is a primary immunodeficiency disease and can be divided into two categories. The most common one is CMC disease (CMCD), which defined as Candida infection confined to the surface of the skin and mucous membranes and not complicated by systemic Candida albicans infection or other clinical symptoms. The other category is systemic CMC (SCMC) complicated by infections caused by other pathogens, systemic invasive fungal infections, or other clinical symptoms apart from the symptoms of CMCD. It is currently believed that both CMCD and SCMC are related to immunodeficiency caused by gene mutations related to IL-17 signal pathway. The inhibited Th17 proliferation, decreased secretion of IL-17 or IL-22 cytokine, or increased IL-17 or IL-22 neutralizing antibody induced by the mutations promoted the susceptibility to Candida or other pathogens. In the treatment of CMC, in addition to the traditional antifungal drugs such as azoles, polyenes and echinocandins, biological agents and target gene therapy offer potential new therapeutic strategies. This article reviewed the association between congenital immunodeficiency in the IL-17 signaling pathway and CMC, and the possible immunological therapeutic approaches and new therapeutic targets.
